Look for:

Our offer for

MARINOMED BIOTECH AG


ISIN:
ATMARINOMED6
WKN:
-
2021/10/22 17:35:19
Price
107.00 EUR
Difference 0.94% (1.00)

General attributes

ISINATMARINOMED6
SymbolMARI
ExchangeVienna Stock Exchange
CurrencyEUR
SectorOther
Security typeStock
Market cap (m)158 EUR
BenchmarkATX AUSTRIAN TRADED INDEX

Market data

Bid (Bid size)-
Ask (Ask size)-
Open106.00 EUR
High107.00 EUR
Low105.00 EUR
Close (prev. day)106.00 EUR
VWAP105.963337 EUR
Volume (pcs)2,823
Trading volume299,134.50
Number of trades14
Last size10

Futures and Options

Related Futures-
Related Options-

PDF Downloads

Company report: MARINOMED BIOTECH AGPDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



2021/10/22 17:35:19
Price
107.00 EUR
Difference 0.94% (1.00)

General attributes

ISINATMARINOMED6
SymbolMARI
ExchangeVienna Stock Exchange
CurrencyEUR
SectorOther
Security typeStock
Market cap (m)158 EUR
BenchmarkATX AUSTRIAN TRADED INDEX

Market data

Bid (Bid size)-
Ask (Ask size)-
Open106.00 EUR
High107.00 EUR
Low105.00 EUR
Close (prev. day)106.00 EUR
VWAP105.963337 EUR
Volume (pcs)2,823
Trading volume299,134.50
Number of trades14
Last size10

Performance and Risk

6m1Y3Y
Perf (%)-23.10%--
Perf (abs.)-32.00--
Beta0.110.110.18
Volatility25.4125.2125.21
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)106.50 EUR (1,459)
Ø price 30 days | Ø volume 30 days (pcs.)112.83 EUR (651)
Ø price 100 days | Ø volume 100 days (pcs.)115.67 EUR (711)
Ø price 250 days | Ø volume 250 days (pcs.)121.32 EUR (1,169)
YTD High | date147.00 EUR (2021/02/19)
YTD Low | date103.00 EUR (2021/07/15)
52 Weeks High | date147.00 EUR (2021/02/19)
52 Weeks Low | date103.00 EUR (2021/07/15)

All listings for MARINOMED BIOTECH AG

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Vienna Stock Exchange2021/10/2217:35107.00 EUR0.3014
Tradegate2021/10/2222:27105.50 EUR0.014
Stuttgart2021/10/2215:31104.00 EUR0.007
Munich2021/10/2208:04107.00 EUR0.002
Frankfurt2021/10/2212:11106.00 EUR0.011
Duesseldorf2021/10/2219:01106.00 EUR0.0015
Berlin2021/10/2218:47107.00 EUR0.0014

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=141937&ID_TYPE_IMAGE_LOGO=2

Contact Details

MARINOMED BIOTECH AG
- -
Hovengasse 25 - 2100 Korneuburg
Telefon: 43-1-2262-90300
Fax: 43-1-25077-4493
E-mail: office@marinomed.com

PDF Downloads

Company report: MARINOMED BIOTECH AGPDF Download

Company Profile

Marinomed Biotech AG is a biopharmaceutical company, which engages in the development of therapies based on patent protected technology platforms. It operates through the Carragelose and Marinosolv segments. The Carragelose segment contains products with anti-viral properties target viral infections of the respiratory tract of different virus strains. The Marinosolv segment refers to the technology platform that increases the bioavailability of hardly soluble compounds for the treatment of sensitive tissues such as nose and eyes. The company was founded by Andreas Grassauer and Eva Prieschl-Grassauer in 2006 and is headquartered in Korneuburg, Austria.

Members of Management Board

Andreas GrassauerChairman of Managing Board
Eva Prieschl-GrassauerMember of Executive Committee
Pascal SchmidtMember of Executive Committee

Board of directors

Simon Jules NebelChairman of Supervisory Board
Gernot HoferMember of Supervisory Board
Brigitte EdererMember of Supervisory Board
Ute LassnigMember of Supervisory Board





Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. For more details please read our Data protection policy.

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.

By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer